This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Acamprosate

Confluence Pharmaceuticals, LLC

Drug Names(s): Acamprosate Calcium

Description: Confluence Pharmaceuticals is developing a product using Acamprosate Calcium. Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcohol withdrawal or benzodiazepine withdrawal.

Deal Structure: AOP Orphan and Confluence
In March 2015, Confluence Pharmaceuticals and AOP Orphan signed a definitive agreement to co-develop and market Confluences lead asset, a product for the treatment of Fragile X Syndrome in Europe and the Middle East.

Partners: AOP Orphan Pharmaceuticals AG


Acamprosate News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug